Cetuximab biosimilar (Shanghai Henlius Biotech)

西妥昔单抗生物类似药（上海复宏汉霖）

Report date: 2026/04/20 20:01:59

Base Information

Drug NameCetuximab biosimilar (Shanghai Henlius Biotech)
Drug Alias Name西妥昔单抗生物仿制药（上海复宏汉霖）Anti-EGFR monoclonal antibody 225 biosimilar重组抗EGFR人鼠嵌合单抗（复宏汉霖）重组抗EGFR人鼠嵌合单克隆抗体（复宏汉霖）HLX-05 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jingze Biotechnology Co LtdFosun Hanlin (Chengdu) Biotechnology Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeL01XC06
Related LinksWikipediaDrugBankKEGG